[Analgesic Therapy of Calciphylaxis with Levomethadone : a Case Study]

Overview

Journal Schmerz

Date 2010 Oct 22

PMID 20963612

Citations 2

Authors

M Poels

R Joppich

K Gerbershagen

F Wappler

Affiliations

Soon will be listed here.

Abstract

Calciphylaxis, or calcific uremic arteriopathy, is a rare complication of end-stage renal impairment. It is characterized by calcification of arterioles and development of intensely painful subcutaneous ischemic ulcerations. While symptomatic management is the mainstay of treatment, particular emphasis is placed on adequate analgesia. Conventional analgesic concepts have mostly proved to be insufficient which increases the extreme suffering of patients. This case report describes the successful analgesic treatment of calciphylaxis with levomethadone.

Citing Articles

Treatment of painful calciphylaxis with methadone in a palliative care unit: A case report.

King S, Kondasinghe J Clin Nephrol Case Stud. 2023; 11:6-11.

PMID: 36688187 PMC: 9850246. DOI: 10.5414/CNCS110985.

Update on cutaneous calciphylaxis.

Wollina U Indian J Dermatol. 2013; 58(2):87-92.

PMID: 23716795 PMC: 3657275. DOI: 10.4103/0019-5154.108026.

References

Mazhar A, Johnson R, Gillen D, Stivelman J, Ryan M, Davis C . Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001; 60(1):324-32. DOI: 10.1046/j.1523-1755.2001.00803.x. View

Elsner F, Sabatowski R, Radbruch L . [Emergency pain treatment--ambulatory intravenous morphine titration in a patient with cancer pain]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2000; 35(7):462-4. DOI: 10.1055/s-2000-5941. View

Rogers N, Coates P . Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens. 2008; 17(6):629-34. DOI: 10.1097/MNH.0b013e32830f4566. View

Mercadante S, Arcuri E . Hyperalgesia and opioid switching. Am J Hosp Palliat Care. 2005; 22(4):291-4. DOI: 10.1177/104990910502200411. View

Davison S, Mayo P . Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag. 2009; 4(6):335-6, 339-44. View

Schliep S, Schuler G, Kiesewetter F . Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol. 2008; 18(5):554-6. DOI: 10.1684/ejd.2008.0499. View

Ketteler M, Schlieper G, Floege J . Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension. 2006; 47(6):1027-34. DOI: 10.1161/01.HYP.0000219635.51844.da. View

Podymow T, Wherrett C, Burns K . Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant. 2001; 16(11):2176-80. DOI: 10.1093/ndt/16.11.2176. View

Green J, Green C, Minott S . Calciphylaxis treated with neurolytic lumbar sympathetic block: case report and review of the literature. Reg Anesth Pain Med. 2000; 25(3):310-2. DOI: 10.1016/s1098-7339(00)90018-x. View

10.

Randinitis E, Posvar E, Alvey C, Sedman A, Cook J, Bockbrader H . Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003; 43(3):277-83. DOI: 10.1177/0091270003251119. View

11.

Matsui A, Williams J . Activation of µ-opioid receptors and block of Kir3 potassium channels and NMDA receptor conductance by L- and D-methadone in rat locus coeruleus. Br J Pharmacol. 2010; 161(6):1403-13. PMC: 3000663. DOI: 10.1111/j.1476-5381.2010.00967.x. View

12.

Llach F, Velasquez Forero F . Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis. 2001; 38(5 Suppl 5):S20-33. DOI: 10.1053/ajkd.2001.28113. View

13.

Schlieper G, Brandenburg V, Ketteler M, Floege J . Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol. 2009; 5(9):539-43. DOI: 10.1038/nrneph.2009.99. View

14.

Inturrisi C . Pharmacology of methadone and its isomers. Minerva Anestesiol. 2005; 71(7-8):435-7. View

15.

Polizzotto M, Bryan T, Ashby M, Martin P . Symptomatic management of calciphylaxis: a case series and review of the literature. J Pain Symptom Manage. 2006; 32(2):186-90. DOI: 10.1016/j.jpainsymman.2006.03.009. View

16.

Lobo E, Heathman M, Kuan H, Reddy S, OBrien L, Gonzales C . Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. Clin Pharmacokinet. 2010; 49(5):311-21. DOI: 10.2165/11319330-000000000-00000. View

17.

Nauck F, Ostgathe C, Dickerson E . A German model for methadone conversion. Am J Hosp Palliat Care. 2001; 18(3):200-2. DOI: 10.1177/104990910101800312. View